A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Live

Grants and Contracts Details

StatusActive
Effective start/end date1/31/221/16/25

Funding

  • Pharmaceutical Research Associates: $44,201.00